These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper. Kowalski ML; Agache I; Bavbek S; Bakirtas A; Blanca M; Bochenek G; Bonini M; Heffler E; Klimek L; Laidlaw TM; Mullol J; Niżankowska-Mogilnicka E; Park HS; Sanak M; Sanchez-Borges M; Sanchez-Garcia S; Scadding G; Taniguchi M; Torres MJ; White AA; Wardzyńska A Allergy; 2019 Jan; 74(1):28-39. PubMed ID: 30216468 [TBL] [Abstract][Full Text] [Related]
11. Can nasal acetylsalicylic acid challenge predict the severity of non-steroidal anti-inflammatory drugs (NSAIDs)-exacerbated respiratory disease (N-ERD)? . Förster-Ruhrmann U; Tietz AK; Kim J; Liebers U; Szczepek AJ; Olze H Allergol Select; 2020; 4():135-143. PubMed ID: 33393939 [TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of lower airway inflammation in patients with NSAID-exacerbated respiratory disease. Jakiela B; Soja J; Sladek K; Przybyszowski M; Plutecka H; Gielicz A; Rebane A; Bochenek G J Allergy Clin Immunol; 2021 Apr; 147(4):1269-1280. PubMed ID: 32810516 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials. Mullol J; Laidlaw TM; Bachert C; Mannent LP; Canonica GW; Han JK; Maspero JF; Picado C; Daizadeh N; Ortiz B; Li Y; Ruddy M; Laws E; Amin N Allergy; 2022 Apr; 77(4):1231-1244. PubMed ID: 34459002 [TBL] [Abstract][Full Text] [Related]
14. Inheritance of NSAID-Exacerbated Respiratory Disease. Suikkila A; Lyly A; Hafrén L; Saarinen R; Klockars T Otolaryngol Head Neck Surg; 2023 Mar; 168(3):540-543. PubMed ID: 35639475 [TBL] [Abstract][Full Text] [Related]
15. Erratum to "IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper" [World Allergy Organ J 13/2 (2020) 100080]. Ansotegui IJ; Melioli G; Canonica GW; Caraballo L; Villa E; Ebisawa M; Passalacqua G; Savi E; Ebo D; Gómez RM; Luengo Sánchez O; Oppenheimer JJ; Jensen-Jarolim E; Fischer DA; Haahtela T; Antila M; Bousquet JJ; Cardona V; Chiang WC; Demoly PM; DuBuske LM; Ferrer Puga M; Gerth van Wijk R; González Díaz SN; Gonzalez-Estrada A; Jares E; Kalpaklioğlu AF; Kase Tanno L; Kowalski ML; Ledford DK; Monge Ortega OP; Morais-Almeida M; Pfaar O; Poulsen LK; Pawankar R; Renz HE; Romano AG; Rosário Filho NA; Rosenwasser L; Sánchez Borges MA; Scala E; Senna GE; Sisul JC; Tang MLK; Yu-Hor Thong B; Valenta R; Wood RA; Zuberbier T World Allergy Organ J; 2021 Jul; 14(7):100557. PubMed ID: 34221218 [TBL] [Abstract][Full Text] [Related]
16. NSAID-ERD Syndrome: the New Hope from Prevention, Early Diagnosis, and New Therapeutic Targets. Laidlaw TM; Levy JM Curr Allergy Asthma Rep; 2020 Mar; 20(4):10. PubMed ID: 32172365 [TBL] [Abstract][Full Text] [Related]
17. Comparison of omalizumab and mepolizumab treatment efficacy in patients with atopic and eosinophilic "Overlap" severe asthma: Biological agent preference in atopic-eosinophilic severe asthma. Tepetam FM; Akyildiz AB; Özden Ş; Örcen C; Yakut T; Atik Ö Medicine (Baltimore); 2023 May; 102(18):e33660. PubMed ID: 37144999 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the clinical outcomes of patients with NSAID-exacerbated respiratory disease receiving aspirin or biologicals. Tuncay G; Damadoglu E; Cihanbeylerden M; Can Bostan O; Kayıkcı H; Özer S; Karakaya G; Kalyoncu AF J Asthma; 2023 Oct; 60(10):1885-1894. PubMed ID: 36971076 [TBL] [Abstract][Full Text] [Related]
19. Severe asthma concomitant with allergic bronchopulmonary aspergillosis (ABPA) and non-steroid exacerbated respiratory disease (N-ERD) successfully treated with mepolizumab: A case report. Çakmak ME Tuberk Toraks; 2022 Jun; 70(2):215-219. PubMed ID: 35785889 [TBL] [Abstract][Full Text] [Related]